Global Depression Treatment Market Report 2022 to 2032: Featuring AbbVie, Jubilant Generics, Sanis Health, Abbott Laboratories and Aurobindo Pharma Among Others
04 nov. 2022 08h46 HE
|
Research and Markets
Dublin, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The "Depression Treatment Market" report has been added to ResearchAndMarkets.com's offering.A recent market study published on the depression treatment...
With 9.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 2.83 Billion by 2029
04 nov. 2022 06h39 HE
|
Fortune Business Insights
Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...
Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute
25 oct. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 25 October 2022 at 9 AM (EEST) Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Global Depression Treatment Therapy Market Report 2022-2028: Selective Serotonin Reuptake Inhibitors (SSRIs) Hold Significant Share
10 oct. 2022 06h43 HE
|
Research and Markets
Dublin, Oct. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
Nexstim NBS 5+ System Continues to Generate Interest in the US
06 oct. 2022 05h00 HE
|
Nexstim Oyj
Press release, Helsinki, 6 October 2022 at 12 PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs....
Pacific Solstice Offers Mental Health Program That Quickens Progress in Junior High and High School Students
09 sept. 2022 09h00 HE
|
Pacific Solstice
MISSION VIEJO, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- "Recent national surveys of young people have shown alarming increases in the prevalence of certain mental health challenges— in 2019, one...
Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital
02 juin 2022 03h00 HE
|
Nexstim Oyj
Press release, Helsinki, 2 June 2022 at 10 AM (EEST) Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") today...
Nexstim Receives an NBS 5+ System Order from a US Customer
06 avr. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 6 April 2022 at 9 AM (EEST) Nexstim Receives an NBS 5+ System Order from a US Customer Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received...
Nexstim Receives a System Upgrade Order from a Customer in Finland
16 févr. 2022 02h30 HE
|
Nexstim Oyj
Press release, Helsinki, 16 February 2022 at 9:30 AM (EET) Nexstim Receives a System Upgrade Order from a Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received...
Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi neuropsykiatrisien häiriöiden hoitoon
14 févr. 2022 02h00 HE
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 14.2.2022 klo 9.00 (EET) Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi...